Geovax Labs Inc (GOVX)
3.186
-0.36
(-10.24%)
USD |
NASDAQ |
Jun 28, 16:00
3.05
-0.14
(-4.28%)
After-Hours: 06:22
Geovax Labs SG&A Expense (TTM): 6.028M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 6.028M |
December 31, 2023 | 6.022M |
September 30, 2023 | 6.185M |
June 30, 2023 | 5.783M |
March 31, 2023 | 5.259M |
December 31, 2022 | 4.987M |
September 30, 2022 | 4.378M |
June 30, 2022 | 3.886M |
March 31, 2022 | 3.684M |
December 31, 2021 | 3.577M |
September 30, 2021 | 3.394M |
June 30, 2021 | 3.072M |
March 31, 2021 | 2.765M |
December 31, 2020 | 2.196M |
September 30, 2020 | 1.788M |
June 30, 2020 | 1.645M |
March 31, 2020 | 1.63M |
December 31, 2019 | 1.638M |
September 30, 2019 | 1.686M |
June 30, 2019 | 1.854M |
March 31, 2019 | 1.800M |
December 31, 2018 | 1.647M |
September 30, 2018 | 1.423M |
June 30, 2018 | 1.304M |
March 31, 2018 | 1.297M |
Date | Value |
---|---|
December 31, 2017 | 1.232M |
September 30, 2017 | 1.644M |
June 30, 2017 | 1.525M |
March 31, 2017 | 1.518M |
December 31, 2016 | 2.131M |
September 30, 2016 | 1.800M |
June 30, 2016 | 1.915M |
March 31, 2016 | 1.935M |
December 31, 2015 | 1.430M |
September 30, 2015 | 1.757M |
June 30, 2015 | 1.840M |
March 31, 2015 | 1.820M |
December 31, 2014 | 1.791M |
September 30, 2014 | 1.583M |
June 30, 2014 | 1.480M |
March 31, 2014 | 1.551M |
December 31, 2013 | 1.792M |
September 30, 2013 | 1.759M |
June 30, 2013 | 1.776M |
March 31, 2013 | 1.853M |
December 31, 2012 | 1.753M |
September 30, 2012 | 2.487M |
June 30, 2012 | 2.736M |
March 31, 2012 | 2.824M |
December 31, 2011 | 2.973M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
1.63M
Minimum
Mar 2020
6.185M
Maximum
Sep 2023
3.663M
Average
3.577M
Median
Dec 2021
SG&A Expense (TTM) Benchmarks
Merck & Co Inc | 10.51B |
Pfizer Inc | 14.85B |
Processa Pharmaceuticals Inc | 4.461M |
Biomea Fusion Inc | 25.24M |
Moderna Inc | 1.518B |